• About us
• Contact

Advertisement

Organisation › Details

Jeito Capital SAS

Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access in Europe & the United States. Jeito Capital has €534 million under management. Jeito Capital is based in Paris with a presence in Europe and the United States. *

 

	Start	2018-06-25 established
	Group	Jeito Capital (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Tordjman, Rafaèle (Jeito Capital 201806– President + Founder before Sofinnova Partners 2001–2017)
	Person 2	Clancy, Annette (Enyo Pharma 201806 Chair of Board of Directors)
	Region	Paris
	Country	France
	Street	33 rue La Fayette
	City	75009 Paris
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	534,000,000 (capital under management (2021) 2021-11-29)
		* Document for »About Section«: Quell Therapeutics Ltd.. (11/29/21). "Press Release: Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform". London & Boston,
		Record changed: 2024-11-12

Advertisement

More documents for Jeito Capital (Group)

• [1] Jeito Capital. (5/22/24). "Press Release: Jeito Capital Announces Acquisition of Portfolio Company HI-Bio by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 Billion". Paris....
• [2] NMD Pharma A/S. (11/15/23). "Press Release: NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing". Aarhus....
• [3] Alentis Therapeutics AG. (4/13/23). "Press Release: Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1". Basel....
• [4] Catalym GmbH. (11/22/22). "Press Release: Catalym Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors". Oxford....
• [5] CDR-Life AG. (4/13/22). "Press Release: CDR-Life Announces $76 Million Raised in Series A Funding". Zürich....
• [6] Jeito Capital. (2/22/22). "Press Release: Jeito Capital Co-leads $65 Million Series A Financing in EyeBio". Paris....
• [7] Jeito Capital. (2/17/22). "Press Release: Jeito Capital Announces the Appointments of Dr Andreas Wallnöfer as Partner Investor and Isabelle Meyrier as Head of Legal". Paris....
• [8] NMD Pharma A/S. (2/15/22). "Press Release: NMD Pharma Raises €35 Million in a New Financing". Aarhus....
• [9] Quell Therapeutics Ltd.. (11/29/21). "Press Release: Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform". London & Boston,...
• [10] Jeito Capital. (9/20/21). "Press Release: Jeito Capital Becomes Key Player in the Financing of Life Sciences in Europe with the Closing of Jeito I at €534 million ($630 million)". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.